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1. INTRODUCTION 
 
 Although the rate of clinical autopsies has been declining drastically for 
decades, it remains an important tool of quality control in clinical practice. It serves to 
determine the exact cause of death, reveals unexpected complications of disease 
processes including adverse or any other effects of treatment as well as validates the 
cause of death for epidemiological statistics. Autopsies make important contribution to 
the under- and postgraduate training in medicine. Clinico-pathological studies are of 
major importance, because (agreeing with the Agency for Healthcare Research and 
Quality U.S. Department of Health and Human Services) ‘clinical diagnoses, whether 
obtained from death certificates or hospital discharge data, contain major inaccuracies 
compared with autopsy diagnoses’. 
 Our university hospital has a catchment area of 500 000 inhabitants, and about 
800 acute stroke patients are treated annually in our stroke centre. The ratio of 
thrombolysed patients is 19%, higher than the average of Western-European countries. 
In the everyday clinical practice at admission and during the course of the disease the 
various imaging modalities (CT, MRI) provide the main sources of information on 
structural/morphological changes in the brain. Although all of our acute stroke patients 
are immediately investigated by CT or MRI at admission (and repeated if required by the 
patient’s deteriorating condition), neither ethical nor financial limitations allow 
performing daily CT/MRI during the agony phase for estimating the ‘final’ pathological 
findings of patients with poor outcome. Since the autopsy rate of patients who died at 
our neurology department was more than 90% over the previous years, we had access to 
the results of neuropathological evaluation which is a unique opportunity in the era of 
declining brain autopsy rates. 
 Ischaemic stroke has been in the focus of interest for several years due to its 
high frequency: cerebrovascular diseases are the most frequent diseases of the central 
nervous system; in 2010 the amount of ischaemic stroke cases was estimated 11.57 
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million. The one-third of the patients die, the rate of disability between survivors is high. 
Haemorrhagic infarction is a frequent complication of ischaemic stroke, although it is 
not always accompanied by clinical deterioration. The effect on clinical outcome is also 
unclear and most of the literature data regained from studies on thrombolysis for 
ischaemic stroke, mainly due to the fact that haemorrhagic transformation (HT) is a 
frequent complication of thrombolysis or anticoagulant therapy. Previous studies have 
focused on the possible aetiological role of the following parameters: age, systolic and 
diastolic arterial blood pressure, congestive heart failure, body temperature, serum 
glucose level, treatment with anticoagulants, pre-treatment with aspirin, early ischaemic 
signs on CT, mean infarct volume, plasma matrix metalloproteinase-9. The adequate 
time window for detection of HT is also disputed and autopsy is the method which may 
provide the most reliable data.  
 The urge for translational brain ischaemia research is derived from the clinical 
trials with neuroprotective regimens, which have been shown to be effective in 
experimental animal models but have failed in clinical trials of ischaemic stroke. The 
molecular mechanisms involved in the ischaemic human brain might differ from the 
controlled conditions of the animal experiments, which are performed with relatively 
young animals with no comorbidities or with selected, genetically determined morbidity 
(e.g. spontaneous hypertensive rats). The situation is very different in an aged stroke 
patient with multiple underlying risk factors and concomitant acute cardiovascular or 
respiratory diseases at the presentation of ischaemic stroke.  
 Apoptotic cell death is responsible only for a minority of the cells as compared 
to necrotic cell loss in ischaemic human brain, but is dominant in the penumbra, the target 
of neuroprotective regimens. The concomitant activation of the cell-death receptor 
(extrinsic) and mitochondrial (intrinsic) pathways of apoptosis has been investigated 
thoroughly in rats and mice after middle cerebral artery (MCA) occlusion. The role of 
mitochondria-dependent apoptosis in neurons has not been studied at all in ischaemic 
adult human brains. Only a handful of studies have described the cell death phenomena 
in ischaemic human brains, not to mention in tissues obtained with short post-mortem 
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delay after acute stroke. In experimental animal studies, neuroprotection has been 
suggested to ensue by inhibition of poly(ADP-ribosyl)ation. Furthermore, phase I and II 
clinical trials with PARP-1 inhibitors are underway as cardioprotecting agents or as an 
adjunct chemo- or radiosensitizer therapy. Now, clinical trials with PARP-1 inhibitors in 
ischaemic stroke are not yet found in the databases (e.g. clinicaltrials.gov). Still, stroke 
is suggested to be the prime indication for development of PARP-1 inhibitors.  
 Spontaneous intracerebral haemorrhage (ICH) affects 5 million people annually 
in the world, its incidence is 10-30/100 000/year and it takes 10-15% of all stroke cases. 
ICH has very high mortality; the 30-day mortality is 40%. The 50% of fatal outcome 
happen within the first two post-stroke days. The rate of disability between survivors is 
remarkable, 6 month later only 20% is able to live an independent life. There are much 
less medical or surgical treatment opportunities than in ischaemic stroke. Since no 
evidence-based effective treatment is known to decrease the primary brain injury caused 
by the haemorrhage, the treatment focuses mainly on the prevention of secondary 
injuries. 
 Early prognostication after ICH is riddled with uncertainties. Given this and the 
self-fulfilling pessimistic general opinion of poor outcome, reliable early prognostication 
after ICH can help to avoid a fatalistic approach by the wider care team including family 
members and enables evidence based DNR (do not resuscitate) orders. Thus, deliberated 
guideline-concordant therapy is essential for all ICH patients. Early prognostication 
helps clinicians to reach an objective opinion of predictable outcome. 
 
2. OBJECTIVES OF THE STUDY 
 
I. Clinicopathological analysis of patients who died in the Department of Neurology, 
University of Debrecen, and had brain autopsy in the Neuropathology Laboratory during 
the previous two calendar years.  
Our specific goals were 
6 
 
1) to analyse the correlation between clinical and neuropathological diagnosis in cases 
of fatal ischaemic stroke, to assess the importance of the neuropathological evaluation in 
establishing the true frequency of HT,  
2) to assess the clinically undisclosed findings revealed by the neuropathological analysis 
in a series of consecutive cases reflecting the routine practice of a stroke centre,  
3) to assess the added value of autopsy and neuropathological analysis in the era of 
advanced imaging techniques. 
II. Studying an autopsy cohort of 13 fatal ischaemic stroke cases treated in the 
Department of Neurology, Helsinki University Central Hospital. 
Our specific aims were  
1) to explore neuronal cell death pathways (necrosis, apoptosis) in ischaemic human 
stroke depending on both the post-stroke time and the examined region (core, penumbra, 
contralateral hemisphere) using immunohistochemical and immunofluorescent methods 
(caspase-3, PARP-1, p89 fragment, PAR, TUNEL) 
III. Retrospectively analysing the data gained from a series of patients treated and died 
in the Department of Neurology, University of Debrecen during an 53-month long period 
due to primary intracerebral haemorrhage, combining these with classic, imaging-based 
data gained from CT volumetry in survivors and neuropathological ABC/2 volumetry in 
nonsurvivors.  
Our specific goals were 
1) to assess growth index of haematoma in nonsurvivors using the volumetric data 
assessed by the baseline CT and comparing these with the data obtained from ABC/2 
volumetry by neuropathological examination, 
2, to assess a relatively simple, reproducible, cost-effective scoring system suitable for 
the prediction of 30-day mortality of primary supratentorial ICH.  
 
3. MATERIALS AND METHODS 
 
3.1. Comparison Of Clinical And Neuropathological Diagnoses 
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3.1.1. Patient Selection and Data Collection 
 We retrospectively analysed the clinical records of patients who died in the 
Department of Neurology, University of Debrecen, and had general autopsy in the 
Department of Pathology and brain autopsy in the Neuropathology Laboratory during 
the previous two calendar years. All stroke patients were treated on specialized stroke 
units with multiparametric monitoring. All patients were older than 18 years of age, mean 
age was 62.66 years (SD 6.51). The following data were collected retrospectively from 
the patients' clinical notes: sex, age, survival time after stroke, suspected clinical 
diagnoses, administration of antiplatelets and anticoagulants over the hospitalisation, 
NIHSS (National Institutes of Health Stroke Scale) at admission, results of the performed 
CT, CTA (computed tomography angiography) or MRI examinations and the general 
autopsy findings.  
 Patients with ischaemic cerebral infarction had acute onset focal neurological 
deficit and brain imaging with or without ischaemic lesion.  
 Patients with haemorrhagic stroke had focal neurological deficit and brain 
imaging evidence of intraparenchymal haemorrhage.  
 Patients with primary intracerebral tumours had histologically verified tumour, 
brain imaging evidence of the neoplasm; they were admitted due to disease progression 
(deteriorating hemiparesis, dysphagia or epileptic seizures). Patients with brain 
metastasis had clinically diagnosed or histologically verified extracerebral primary 
tumour, brain imaging evidence of the metastasis; they were admitted due to disease 
progression (increased intracranial pressure or epileptic seizures) or acute ischaemic 
stroke. 
 Patients with central nervous system infection had evidence of neurological 
symptoms or meningeal signs indicative of meningitis or meningo-encephalitis and 
cerebrospinal fluid analysis had evidence of elevated cell count and protein content with 
or without decreased sugar level depending on the infectious agent. 
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3.1.2. Neuropathological Analysis 
 Brains were immersed in 10% buffered formalin according to standard 
procedures to allow good fixation and avoid deformation. We measured the formalin 
fixed whole brain and brainstem&cerebellum weight, respectively, to have the weight 
ratio of the supra- and infratentorial part as an index of atrophy or weight gain (e.g. due 
to oedema). After detailed description of the general appearance coronal slices of 0.75 
cm sickness were cut. This method is adequate to diagnose gross pathologies including 
haemorrhage, infarct, HT and other pathologies such as herniation, secondary brain stem 
haemorrhage, arachnoideal cyst, tumours. After the macroscopic evaluation 
approximately 2x2x0.5 cm tissue blocks were sampled (which fit into standard size 
cassettes used for histotechnical processing) from areas recommended by BrainNet 
Europe (frontal cortex, temporal cortex, cingulate gyrus, parietal cortex, pre- postcentral 
gyrus, occipital cortex, hippocampus anterior, hippocampus posterior, basal forebrain, 
striatum, thalamus, midbrain, pons, medulla, vermis, cerebellum). After histotechnical 
processing and embedding to paraffin wax, sections of 7 µm thickness were cut and 
stained with haematoxylin and eosin (H&E), and luxol fast blue and Nissl (LFB/Nissl) 
to assess basic pathological changes. Evaluation was performed by a neuropathologist 
aware of the sample localization and patient history. The clinical findings were compared 
with the neuropathological results. 
 
3.2. Cell Death Mechanisms in Ischaemic Stroke 
3.2.1. Autopsy Material 
We studied autopsy specimens from 13 cases of fatal ischaemic stroke (symptom 
duration from 15 h to 18 days) treated at the Department of Neurology, Helsinki 
University Central Hospital. Autopsies were performed within a mean of 18.6 h after 
death (range 3.5–40 h). Two patients who died of a non-neurological cause served as 
controls. The study protocol was approved by the institutional review committee of the 
Helsinki University Central Hospital. Informed consent was given by relatives. 
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3.2.2. Neuropathology 
Tissue sampling was based on the most recent CT scan to obtain samples from 
the infarct core and periinfarct area (ipsilateral to thrombosis) and from the 
corresponding areas of the contralateral hemisphere and from the control brains (n=2). 
On autopsy, infarction areas were identified macroscopically and approximately 1-cm3 
cortical samples including subcortical white matter were dissected and fixed with 
formalin prior to embedding in paraffin. Sections of 5 µm were cut and were stained with 
hematoxylin–eosin to confirm ischaemic neuronal changes. Evaluation was performed 
by a neuropathologist unaware of the patient history or the sample localization. Focusing 
on the integrity of the nucleus, scores for signs of ischaemic neuronal changes in each 
tissue section were given. In short, Score 0: normal neuronal morphology; Score 1: 
largely normal morphology but scattered neurons with nuclear abnormalities such as 
pyknosis, low nuclear cytoplasmic contrast and smearing of nuclear border; Score 2: 
large proportion of neurons with nuclear abnormalities, Score 3: large proportion of 
neurons with nuclear abnormalities, with scattered ones with irreversible signs such as 
shrunken cytoplasm with irregular borders and invisible nuclei; and Score 4: large 
proportion of neurons with irreversible changes. When comparing the neuropathological 
scoring with the CT scan and macroscopical sampling in autopsy, the sections with 
scores 0 or 1 were derived from contralateral hemisphere or control areas (ipsi- or 
contralaterally), with scores 2–3 from periinfarct area, and with score 4 from the infarct 
core. 
 
3.2.3. Immunohistochemistry 
The antibodies used were as follows: (1) MoAb rabbit anti cleaved Caspase-3 
(ACA-3); 1:75; (2) MoAb anti poly(ADP-ribose) polymerase against full-length PARP-
1; 1:100; (3) Mouse immunoglobulin G1 (m IgG1) as control antibody for Ab 2; 1:100; 
(4) Pc rabbit anti PARP-1 p85 fragment (Cleaved PARP-1); 1:100; (5) R IgG as control 
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for Ab 4; 1:5000; (6) MoAb anti-PAR; 1:400, (7) M IgG3 as control for Ab 6; 1:400. 
Abbreviations: Pc = polyclonal antibody (Ab). MoAb = monoclonal Ab.  
Paraffin-embedded sections were deparaffinized with xylene and hydrated 
through graded alcohols. Antigen unmasking by microwave irradiation in 0.1 M citrate 
buffer (pH 6.0) twice at 750 W (5 min) and once at 650 W (5 min) was done prior to 
quenching in 0.3% H2O2 in methanol (3% peroxide in aqua for ACA-3 Ab) for 10 min, 
and blocking with 10% normal sera for 30 min (5% normal sera for 1 h for ACA-3 Ab) 
prior to incubation with the primary antibody at +4 °C overnight. Biotinylated secondary 
antibody (1:200; 30 min) was followed by avidin–biotin complex for 30 min. Incubation 
with diaminobenzidine (DAB) according to manufacturer’s instructions was carried out 
prior to counterstaining with Mayer’s hemalum. For cleaved PARP-1 (p85), NovoLinkTM 
detection was carried out according to manufacturers’ recommendation with the 
exception of washing buffer (0.05 M Tris–Hcl pH 7.6, 0.03 M NaCl, 0.1% Tween 20). 
Additional control experiments included omission of the primary or secondary antibody 
in the ABC-method, which resulted in loss of immunoreactivity. For PARP-1 and 
cleaved PARP-1 antibodies, Western blot testing was performed. Preabsorption of 
caspase-3 protein with ACA-3 antibody (1 h, RT) prior to immunohistochemical staining 
abolished immunoreactivity in duplicate experiments.  
 
3.2.4. Western Blotting 
Western blot analysis was used to assess the specificity of PARP-1 antibodies 
(from Serotec and Promega) in differentiating the full-length and cleaved fragment of 
PARP-1. Human recombinant caspase-3 protein was used to cleave purified full-length 
human PARP-1 protein in vitro. PARP-1 protein cleavage by ACA-3 was produced by 
mixing 750 ng of purified ACA-3 with 10 U of full length human PARP and incubating 
the reaction mixture at +37 ˚C for 30 min prior to applying 400 ng of protein/lane for 
separation under reducing conditions on 8% SDS-polyacrylamide gels followed by 
electroblotting to PVFD membranes. PARP-1 was detected by the antibody against full-
lenght PARP-1 (Serotec Ab; dilution 1:1000) and cleaved PARP-1 by Promegas’ 
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antibody against cleaved PARP-1 (p85) (1:1000). Horseradish peroxidase (HRP)-
conjugated goat anti-mouse or anti-rabbit IgG was used as secondary antibody. Protein 
bands were visualized using ECL Plus and Typhoon 9400 Variable Mode Imager. As a 
negative control the primary antibodies were omitted from the protocol resulting in 
abolishment of immunoreactive bands. 
 
3.2.5. Double-Labeling Immunofluorescent Staining of PARP-1 and PAR 
 The antibodies were applied in dilutions similar to immunohistochemistry. 
Paraffin-embedded sections were deparaffinized with xylene and hydrated through 
graded alcohols. Antigen unmasking by microwave irradiation in 0.1 M citrate buffer 
(pH 6.0) once at 750 W (5 min) and twice at 650 W (5 min) was done prior to blocking 
with 0.1 M Tris–Hcl/3% BSA and 20% FBS, pH 7.5 for 30 min. First primary antibody 
was incubated for 1 h (RT) followed by rabbit anti-mouse FITC 1:20 for 1 h (RT). 
Endogenous biotin blocking was performed according to manufacturers’ 
recommendations prior to the second primary antibody incubation at +4C° overnight. 
Anti-mouse or anti-rabbit biotinylated secondary antibody (1:200) was followed by 
NeutrAvidin Rhodamine Red 1:200 for 30 min (RT). The slides were mounted on cover 
slips with Vectashield-DAPI fluorescence mounting media containing 4’,6-diamino-2-
phenylindole. Slides were washed twice in PBS for 5 min between all steps. All steps 
were performed in a humid chamber in dark. 
 
3.2.6. Triple-Labeling Immunofluorescent Staining of in Situ Cell Death Detection 
by TUNEL with ACA-3 and DAPI 
 Microwave irradiation in 0.1 M citrate buffer (pH 6.0) at 370 W (5 min) was 
followed by blocking with 3% bovine serum albumine (BSA) in 20% normal bovine 
serum/0.1 M Tris–HCl (pH 7.5) for 30 min. Overnight incubation with the primary 
antibody (ACA-3) was succeeded by secondary biotinylated antibody at 1:200 dilution 
for 30 min and subsequent detection with RhodamineRed®-conjugated NeutraliteTM 
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avidin at 1:200 dilution (30 min). Subsequently, the TUNEL reaction (terminal 
deoxynucleotidyl transferase (TdT)-mediated dUTP nick end labeling) was carried out 
according to manufacturer’s instructions with a FITC-tag. The sections were mounted 
on cover slips with Vectashield-DAPI fluorescence mounting media containing 4’,6-
diamino-2-phenylindole and then investigated with an epifluorescence microscope.  
 
3.2.7. Acquisition of Microscopical Data and Statistical Analyses 
 The present investigational microscopical data were collected from tissue 
blocks from the infarct and periinfarct region and from homologous regions of the 
contralateral hemisphere. In each section, immunoreactivity was evaluated in five 
consecutive fields of 0.3125 mm2 resulting in a mean (SE) of immunopositive cell 
structures/mm2.  
 Although there is experimental evidence for apoptotic cell death of other cell 
types, including astrocytes, apoptotic cell morphology and TUNEL-labeling have been 
described most prominently as neuronal phenomena, which is in line with results in 
experimental animal model of permanent MCA occlusion. In the present study, we 
concentrated the systematic evaluation of the immunoreactivities on neuronal expression 
of cell death mediators, namely ACA-3 and PARP-1. 
 We confirmed the severity of ischaemic neuronal changes from an adjacent 
section (increasing damage scores from 0 to 4 as described in ‘Neuropathology 3.2.2.’). 
This also made sure that the ischaemic neuronal changes associated with secondary 
ischaemia, e.g. due to bilaterally increased intracranial pressure, were represented as 
early ischaemic changes (i.e. score 1) in the results. The descriptive data are given as 
mean (SE). Statistical analyses were performed as described previously using the SPSS 
for Windows-program (version 13.0). In short, the difference between the mean numbers 
of immunoreactive cell structures/mm2 in each brain location was evaluated by one-way 
ANOVA followed by LSD post hoc test. Jonckheere–Terpstra trend test was applied to 
determine the strength of associations between the continuously distributed variables, 
i.e. median immunoreactivities of ACA-3 and PARP-1 and the class-ordered ischaemic 
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neuronal score. Spearman correlation coefficient (rS) was used to assess the relation 
between PARP-1 and the percentage of TUNEL positive neurons. In the box plots, the 
median line is shown, the bar represents the upper 75% and lower 25% quartile, and the 
error bar depicts high and low values. P values <0.05 were considered statistically 
significant. 
 
3.3. The 30-Day Outcome in Spontaneous Supratentorial Intracranial 
Haemorrhages  
3.3.1. Patient Selection and Data Collection 
We retrospectively reviewed the data of 156 Caucasian patients (71 
nonsurvivors and 85 survivors) with primary supratentorial ICH admitted to our 
Intensive Care Unit (ICU) in a 53-month period. All patients were older than 18 years of 
age and were transported to our ICU within 24 hours of stroke onset. All patients were 
older than 18 years of age and were transported to our ICU, which is a specialized stroke 
unit with multiparametric monitoring, within 24 hours of stroke onset. If this point of 
time could not be ascertained, we used the last time when the patient was known to be 
well. All patients routinely underwent a baseline nonenhanced CT within 30 minutes of 
arrival, and the CT confirmed the ICH. A second CT was obtained on average on the 10th 
day after admission or when symptoms deteriorated. Exclusion criteria were traumatic 
ICH, subarachnoid haemorrhage (SAH), vascular malformation, tumour, HT of 
ischaemic stroke (on admission or any CT performed later), postthrombolytic 
haemorrhage in ischaemic stroke, infratentorial ICH and primary intraventricular 
bleeding. We did not include subjects who had undergone neurosurgical evacuation or 
drainage. All patients were treated on specialized stroke units with multiparametric 
monitoring. 
The following data were collected retrospectively from patients' clinical notes 
partly based on the Debrecen Stroke Database: sex, age, current smoking, excessive 
alcohol consumption, systolic and diastolic arterial blood pressure, and pulse rate at 
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arrival. Laboratory parameters were collected from the initial blood sampling: serum 
sodium, potassium, glucose levels, sedimentation rate, haemoglobin, white blood cell 
(WBC) and platelet counts, liver and kidney function tests and coagulation parameters. 
 
3.3.2. CT Analysis 
Image analysis was carried out retrospectively by two consultant 
neuroradiologists of our Department of Biomedical Laboratory and Imaging Science, 
who were blinded to the outcome. CT scans were performed on two 16-slice MDCT 
(multidetector computed tomography) scanners. Slice thickness was 5 to 10 mms for 
supratentorial and 2.5 to 4 mms for infratentorial regions. Images were transferred to an 
offline image processing workstation as DICOM (Digital Imaging and Communications 
in Medicine) files. Haemorrhage segmentation was carried out using the 3D Slicer 
software package developed by Brigham and Women's Hospital Surgical Planning 
Laboratory and MIT. This procedure allowed separation of the intracranial space from 
the skull and nonbrain structures; however, this method required verification and manual 
detachment of incorrectly labelled areas before performing volumetry with the built-in 
“Measurevol” module. The following variables were constructed: total intracranial 
volume; total haematoma volume; intraparenchymal haematoma volume; and 
intraventricular haematoma volume, each expressed as cm3. Additionally, relative 
volumes were defined as the ratio of total, intraparenchymal and intraventricular 
haematoma volumes to intracranial volume yielding variables (without unit). 
 
3.3.3. Neuropathological Analysis 
 Autopsies were performed within 48 hours after death. In our Neuropathology 
Laboratory, brains fixed in 10% formalin were cut into coronal slices. During the 
examination we verified the clinical diagnosis. Similarly to the in vivo diagnostic, the 
ABC/2 method was used to estimate haematoma volumes based on the assumption that 
the volume of an intracranial haematoma can be approximated by an ellipsoid unless the 
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haematoma is very irregular in shape. Ellipsoids can be described in terms of Cartesian 
coordinates using their three largest perpendicular axes. Consecutive coronal slices were 
laid down with the posterior surface up, and maximal diameters of the haematoma on 
every slice were measured in mms: one in the horizontal direction and another 
perpendicular to that. These two largest diameters were used as A and B in the ABC/2 
formula and were not necessarily on the same brain slice; each slice has been photo 
documented. Although slices were originally 10 mms thick, we measured the thickness 
of each slice at four different locations assuming that the brains may have shrunk during 
fixation. The precise thickness of a slice was obtained as the average of these 
measurements. The resulting numerical data were then summed to obtain the maximum 
diameter of the haematoma perpendicular to the previous ones, which was used as C in 
the ABC/2 formula. In cases when the haematoma did not fully penetrate a slice, that is, 
the first and last brain slice containing the bleeding, we measured the depth of the portion 
of haematoma by sticking a probe into it. Due to fixation in formalin and brain slicing in 
cases of ventricular extension it was not always exactly discernible which part of the 
haematoma was in the parenchyma and in the ventricles, respectively. Therefore the 
haematoma volume calculated by the ABC/2 method was equal to the sum of the 
intraparenchymal and intraventricular parts. Volumes of haemorrhages were converted 
from mm3 to cm3. In these cases the relative haematoma volume was calculated using 
the initial CT intracranial volumetry data (for methods see above). 
 
3.3.4. Statistical Analysis 
The growth index of haematomas was calculated in two steps according to the 
following logistic formulas (log indicates natural logarithm): L=log(hpb2/(1-hpb2))-
log(hpb1/(1-hpb1)), and growth index=exp(L)/(1+exp(L))-0.5, where hpb is haematoma 
per brain; hpb2 is ratio of total haematoma volume obtained by the second volumetry 
(follow-up CT scan in survivors, neuropathological ABC/2 method in nonsurvivors) to 
intracranial volume based on the follow-up CT (survivors) or the first CT (nonsurvivors); 
hpb1 is ratio of total haematoma volume to intracranial volume based on the first CT 
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volumetry (survivors and nonsurvivors). Negative growth indices denote reduction of 
haematoma; positive growth indices denote haematoma expansion. 
Variables were described using mean and SD (continuous variables) or category 
percentages (categorical variables) stratified for survivors and nonsurvivors. 
Associations between explanatory factors and the outcome of death within 30 days were 
evaluated using logistic regression. Curvatures in relationships were assessed and 
allowed for by transformation or by adding a squared term if this substantially improved 
model fit. Variables showing remarkable associations in unadjusted models were 
selected for multiple regression modeling unless they are collinear with each other, in 
which case elimination was carried out on grounds of clinical practicability. Left-out 
variables were assessed for their potential contribution by adding to the prefinal multiple 
model one by one and left in if found clinically remarkable or statistically significant. 
The final multiple logistic regression model was checked for goodness of fit using the 
Hosmer-Lemeshow test. The level of significance was set at α=0.05. To create the 
scoring system, model-predicted probabilities of outcome were generated for all subjects, 
and statistics for the minimum, the 10th, 20th,…, 90th percentage points, and the maximum 
were derived from the resulting set of values. The coefficients of the final model were 
built into a spreadsheet-based calculation interface which places any patient, with given 
input data, in terms of probability-of-death percentage range, given the percentage points 
observed on our sample of patients. All analyses were performed using Stata Statistical 
Software (StataCorp. 2009). 
 
4. RESULTS 
 
4.1. Comparison of Clinical And Neuropathological Diagnoses 
 All patients (n=100) had brain CT at admission. In possible thrombolysis 
candidates, computed tomography angiography (CTA) was also performed at arrival and 
all thrombolysed patients had a second control CT within 24 hours after thrombolysis. 
Repeat CT were done if the patient’s condition deteriorated (loss of consciousness, 
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paresis, new clinical symptoms, etc.) to exclude any treatable cause of deterioration (e.g. 
haemorrhage, HT, secondary brainstem haemorrhage, oedema, etc.).  
 Clinically 64 patients (62.74%, female n=40, male n=24, mean age 62.6 years, 
SD 6.51) were diagnosed with acute ischaemic stroke during hospitalisation, regardless 
of CT signs of ischaemic infarct or absence of it at admission. In 10 of these patients HT 
of the infarct was diagnosed already by the clinicians. At autopsy we found territorial 
ischaemia in 59 patients and lacunar infarct(s) in 5 patients. Brain autopsy revealed HT 
in 34 cases (16 thrombolysed and 18 non-thrombolysed patients). We classified 
haemorrhagic infarcts as previously reported: HI1: small petechiae, HI2: more confluent 
petechiae, PH1: ≤30% of the infarcted area with some mild space-occupying effect, PH2: 
> 30% of the infarcted area with significant space-occupying effect, or clot remote from 
infarcted area. The distribution of HT in our material was the following: HI1 26.5%, HI2 
29.4%, PH1 29.4% and PH2 14.7%.  
  None of the patients with HT received oral anticoagulant over their 
hospitalisation, although 4 of them were on coumarin or warfarin therapy at admission 
with ineffective INR (<1.7) level. Thirty-one patients received prophylactic low 
molecular weight heparin (LMWH) therapy and 17 patients received antiplatelet therapy. 
 According to CT, brain haemorrhage was the clinical diagnosis in 22 patients 
(21.56%, female n=6, male n=16, mean age 75 years, SD 19.7). The neuropathological 
findings were confirmatory in all clinically diagnosed haemorrhagic cases. According to 
the clinical records in one case trauma, in another case anticoagulant side effect was the 
aetiological factor. Underlying neuropathology in the background of cerebral bleeding 
was revealed in two cases (cerebral amyloid angiopathy and arteriovenous malformation, 
respectively). Brain autopsy revealed one clinically unknown cerebral haemorrhage; the 
male patient admitted with symptoms of mild vertebrobasilar insufficiency died 
unexpectedly, neuropathological evaluation described severe subarachnoideal 
haemorrhage as a consequence of ruptured basilar arterial aneurysm. 
 Neuropathological evaluation confirmed all primary brain tumours (n=3) and 
metastases (n=4) cases. The primary brain tumours were anaplastic astrocytoma in 2 
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patients and gliosarcoma in 1 patient. The metastases originated from pulmonary 
adenocarcinoma (n=1), invasive ductal breast cancer (n=1), sigillocellular gastric cancer 
(n=1) and carcinoma of the uvula in the oral cavity (n=1), respectively. 
 Infections of the central nervous system (CNS) were diagnosed clinically in 2 
patients. The brain autopsy confirmed the meningitis in both patients.  
 In four cases with not life-threatening neurological conditions (e.g. neuronal 
heterotopy and microgyrification; arachnoideal cyst; silent aneurysm; opalescent 
meninges with mild mononuclear infiltration as a late consequence of a previous 
meningitis) the neuropathological evaluation confirmed the clinical diagnoses. 
 
4.2. Cell Death Mechanisms in Ischaemic Stroke 
4.2.1. Western Blotting 
 In Western blotting with purified PARP-1 protein, the PARP-1 antibody against 
full-length PARP-1 (Serotec) detected both a band of 116 kDa (equivalent to full-length 
PARP-1) and a less intense band of the size 89 kDa. PARP-1 protein cleavage by ACA-
3 in vitro prior to Western blotting resulted in complete loss of signal for full-length 
PARP-1. Antibody against cleaved PARP-1 (Promega) detected only a band 
corresponding to cleaved PARP-1 (89 kDa). 
Later in the text, PARP-1 refers to full-length PARP-1 (not totally excluding minor 
detection of cleaved PARP-1 p89 fragment) and cleaved PARP-1 to detection of p85 
fragment using the specific antibody (Promega) in immunohistochemistry.  
 
4.2.2. PARP-1 Immunoreactivity 
 Only scattered neurons showed PARP-1 immunoreactivity in control brains 
(n=2). Post-ischaemic PARP-1 immunoreactivity was evident both in neuronal nuclei 
and in cytoplasm. Interestingly, postischaemic PARP-1 immunoreactivity was also 
evident in the nucleolus. The maximum number of PARP-1 positive neuronal nuclei was 
evident in the infarct core during the first post-ischaemic day and this shifted to the 
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periinfarct area during the second day (highest at 23 h vs. at 39 h, respectively). The 
mean number of PARP-1 immunoreactive neuronal nuclei was the highest in the 
periinfarct area. Interestingly, the nuclear PARP-1 positivity correlated with increasing 
neuronal ischaemic (necrosis) score with the exception of most dense ischaemic damage 
(Score 4; only 2 brain sections). The induction was evident up to 2 weeks.  
 The number of neurons with cytoplasmic PARP-1 immunoreactivity was the 
highest in the periinfarct region compared to infarct core area (4.6 (SE 0.8) vs. 2.3 (SE 
0.5); p=0.028). Cytoplasmic PARP-1 immunoreactivity followed a similar temporal 
course with maximum induction at 3 days like nuclear PARP-1. The cytoplasmic PARP-
1 immunoreactivity correlated with increased percentage of TUNEL-labeled cells in the 
brain regions with neuronal ischaemic scores 2, 3 or 4, i.e. the periinfarct and infarct core 
regions (p=0.01) up to 6th days survival time.  
 
4.2.3. Post-Ischaemic Cleaved PARP-1 Immunoreactivity 
 The maximum number of neuronal nuclei immunoreactive for cleaved PARP-1 
was observed between 3 days and 2 weeks compared with the peak in less than 3 days 
for PARP-1. The number of nuclei immunoreactive for cleaved PARP-1 correlated with 
increasing neuronal ischaemic score with the exception of most dense ischaemic damage 
(p=0.009). The maximum number of neuronal cytoplasm expressing cleaved PARP-1 
was evident by less than 3 days. The cytoplasmic cleaved PARP-1 expression was in 
inverse correlation with increasing neuronal ischaemia score (p=0.001). 
 
4.2.4. PAR-Polymer Immunoreactivity 
 PAR immunoreactivity was prominent in the cytoplasm of neurons in the 
control brains. PAR immunoreactivity was very intense both in the neuronal nuclei and 
cytoplasm in two brain sections from the periinfarct area with a neuronal ischaemia score 
2 (Cases 1 and 6). 
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PAR immunoreactivity was mostly seen in the neuronal nuclei in two brain sections 
(Cases 12 and 13) with advanced ischaemic damage (Score 4; infarct core).  
 
4.2.5. Double Labeling of PARP-1 and PAR 
 The amount of neuronal somas immunofluorescent for cleaved PARP-1 (p85) 
was bigger than for full-length PARP-1 (Case 2) in keeping with the results from 
immunohistochemical staining. PAR-fluorescence in neuronal nuclei colocalized both 
with the full-length and cleaved PARP-1 enzyme. Less PAR-immunofluorescent cells 
were detected in a section from the contralateral hemisphere (Case 2). 
 
4.2.6. ACA-3 Immunoreactivity 
 ACA-3 immunoreactivity was seen only in scattered cells in the control brains 
(n=2). Post-ischaemic ACA-3 expression became evident in the cytoplasm of the gray 
matter neurons after 15 h of ICA occlusion. About a fourfold increase in the number of 
ACA-3 immunopositive neurons was detected in the infarct core very acutely and it 
subsided during the following days up to 1 week. In the periinfarct area, the magnitude 
of the increase in the number of ACA-3 immunoreactive neurons was roughly threefold, 
and it tended to be increased up to a week. A decrease in the number of ACA-3 positive 
neurons between the groups of acute ischaemia (<3 days of symptoms) and >2 weeks 
ischaemia duration was detected (p=0.002). In the contralateral hemisphere, neuronal 
ACA-3 immunoreactivity showed an increasing trend up to 3 days, after which the 
number of ACA-3-positive neurons was equivalent to controls (n=2). ACA-3 expression 
was seen in the neuronal processes in the infarct core on the 2nd day after MCA occlusion 
(Case 4). In double-labeling immunofluorescence, ACA-3 positive neuronal processes 
colocalized to some extent with the TUNEL-positive nuclei. 
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4.3. The 30-Day-Outcome in Spontaneous Supratentorial Intracranial 
Haemorrhages 
Of the 81 survivor patients, eight were excluded because they did not have a 
second CT. Of the 75 nonsurvivor patients we excluded two based on brain autopsy 
results: ruptured aneurysm of the MCA and a metastatic tumour, respectively, had been 
confirmed. Twelve brains were unsuitable for volumetry due to fragmented, multilobar 
haematomas or having been damaged during removal from the skull, cases in which the 
ABC/2 method fails to accurately estimate haemorrhage volumes. In addition, medical 
records were not sufficiently detailed in a total of nine cases. Thus, we analyzed the 
complete dataset of 59 nonsurvivor and 66 survivor patients. 
 
4.3.1. Predictors of 30-Day Mortality 
The relationship between age and greater odds of death was of borderline 
significance. Higher systolic blood pressure at admission was a predictor of lethal 
outcome. Other variables, including sex, alcohol consumption, smoking and pulse rate 
at admission, were not significantly associated with mortality.  
There was no statistical significance regarding sex, current smoking, excessive 
alcohol consumption, diastolic arterial blood pressure and pulse rate at arrival. 
Laboratory parameters were collected from the initial blood sampling: serum sodium, 
potassium, glucose levels, sedimentation rate, haemoglobin, white blood cell (WBC) and 
platelet counts, liver and kidney function tests, and coagulation parameters. Of these, 
serum potassium concentration was significantly associated with fatal outcome: high and 
low levels outside the normal range both represented elevated odds of death. We 
identified higher serum glucose concentration and lower platelet count as further 
predictors of fatal outcome. 
Comparing CT characteristics and volumetric findings between survivors and 
nonsurvivors, the mean time from symptom onset to initial CT was strongly and 
inversely related to occurrence of death within 30 days. In the survivor group, the mean 
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time between baseline and second CT was 10.7 (SD 5.05) days; in the nonsurvivor group, 
the mean time between symptom onset and death was 7.7 (SD 6.4) days. Differences 
between the two groups in absolute volumes of total and intraparenchymal haematoma 
on baseline CT were strongly significant, similarly to relative haematoma volumes. The 
growth index of haematoma was found to be a very strong predictor of the outcome. The 
early presence of intraventricular haemorrhage and its volume was also strongly 
associated with fatal outcome. There was an approximate 43% decrease in the mean 
volume of total haemorrhage from baseline to follow-up CT in survivors and a 54% 
increase from initial CT to death in the other group and, consistently, there was a 42% 
decrease in survivors and a 56% increase in nonsurvivors in relative total haematoma 
volume. Intraventricular extension of the haematoma was more frequent in the 
nonsurvivor group both on initial CT and on follow-up examinations. 
 
4.3.2. The SUSPEKT Scoring System 
 The final multiple logistic regression model showed statistically significant 
associations between 30-day case fatality and a number of variables: serum glucose 
(Sugar); total haematoma volume (Size); systolic blood Pressure; presence of 
intraventricular haemorrhage (Extension to the ventricular system); and serum potassium 
level (Kalium). Using these and adding age (lifeTime) which was of borderline 
significance we developed the six-factor scoring system SUSPEKT. The SUSPEKT 
scoring system is suitable for prediction of 30-day mortality after primary supratentorial 
ICH. Probability (pr) can be derived by summing all bx (product of means observed in 
the present study and coefficients) values (sbx), and using the formula esbx/(1 + esbx), 
where e denotes Euler's number. Probability (pr) may be referred by a table of 
percentiles.  
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5. DISCUSSION 
 
5.1. Comparison of Clinical And Neuropathological Diagnoses 
 The Department of Neurology, University of Debrecen is a regional stroke 
centre explaining the predominance of stroke patients in our autopsy series.  
 Brain autopsy confirmed the clinical diagnoses in all cases of cerebral 
haemorrhages, primer and metastatic tumours and central nervous system infections. 
Neuropathological evaluation revealed the aetiology in two cases with parenchymal 
bleeding; it described cerebral amyloid angiopathy in one and arteriovenous 
malformation in another case. Only brain autopsy could reveal a clinically unknown 
cerebral haemorrhage; the male patient was admitted with symptoms of mild 
vertebrobasilar insufficiency, while neuropathological evaluation described severe 
subarachnoideal haemorrhage in the background of unexpected death as a consequence 
of ruptured basilar arterial aneurysm. 
 Autopsy provided the most additional information in ischaemic stroke cases. 
There are not many clinico-pathological reports on consecutive autopsy series with 
predominantly stroke cases and only few with special emphasis on HT in ischaemic 
infarcts. The reported frequency of HT in previous studies depended on several factors, 
e.g. whether the study was based on imaging methods or on autopsy results, whether the 
patients had received anticoagulant, antithrombotic or fibrinolytic treatment, or on the 
post-stroke time of control imaging modality. Additionally the results of the clinical and 
neuropathological diagnostic tools are heterogenous, difficult to compare them, and the 
population examined can make it even more heterogenous due to the fact that autopsy 
results can be gained from fatal cases exclusively. Kerényi et al. analysed an autopsy 
series of 245 patients with ischaemic stroke with HT in 29%. Lodder et al. reported an 
autopsy series with 48 patients dying within 15 days following a supratentorial cerebral 
infarct. In their analysis 16 patients (33%) had HT. Toni et al. examined 150 consecutive 
patients with cerebral infarct in the anterior circulation. They performed CT or autopsy 
one week after the stroke and observed HT in 43%, mostly (89%) petechial 
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transformations and in 11% larger haematomas. Celik et al. evaluated a series of 86 MCA 
territorial infarction cases, who had received before neither antiplatelet nor anticoagulant 
therapy. By the follow up CT performed 72 hours after stroke they found HT in 8.5% of 
all examined patients, but in 40.6% of MCA territorial infarction cases. Okada et al. 
examined 160 acut ischaemic stroke patients. Their CT based results showed all together 
40.6% HT, from which 15.4% could be seen in the first 1-4 days, 67.7% in the first 10 
days and 100% within the first 30 days and they haven’t detected any new HTs after the 
first month. Hornig et al. evaluated 65 patients’ data. They detected HT with brain CT 
in 28 cases, 40% in the first week, and the rest 60% in the second post-stroke week. 
These earlier reports show how difficult is to define the most appropriate time for the 
diagnosis of HT. Furthermore, diagnostic possibilities are often different in the routine 
practice as compared to well-defined and sponsored studies which last for a particular 
period of time. Moreover, ischaemic stroke patients usually have days or weeks (in our 
sample 11.71 days, SD 13.16) before death with reduced level of consciousness and 
critical medical status. Therefore, the premortal diagnosis of HT could only be possible 
with daily repeat CT or MRI during the critically ill period, which is not possible from 
both the ethical and financial point of view. Repeat CT are done in all thrombolysed 
patients within 24 hours after thrombolysis, but not necessarily perfomed in non-
thrombolysed patients, if the patient’s condition does’t require or allow it. However it is 
well established that HT is not necessarily accompanied by deterioration of neurological 
status.  
 The reported frequency of the different types of HT in the literature depends on 
the treatment used in the acute phase of ischaemic stroke, but also on the HT subtypes’ 
definitions used in that particular source. The distribution of HT in our material was the 
following: HI1 26.5%, HI2 29.4%, PH1 29.4% and PH2 14.7%. Okada et al. defined 
four types of HT: spotty and scattered petechial haemorrhage, along the cortical margin 
of the ischaemic lesion (56.9%), diffuse haemorrhage (18.5%), small (<3 cm in diameter) 
(13.8%) and massive (>3 cm in diameter) (10.8%) haematoma. Fiorelli et al. examined 
the subtypes and frequency of HT after iv. rtPA treatment in the ECASS I. HT detection 
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was based on control brain CT performed 36 hours later. Due to the very different patient 
population from ours and the exclusively imaging based HT diagnosis, the comparison 
between their and our results is meaningless. However, their results support those 
previous findings that the frequency and even the severity of HT are higher after rtPA 
treatment. In our sample most of the PH1-2 transformations developed in thrombolysed 
patients. The high proportion of HT in our sample diagnosed only at brain autopsy can 
be explained partially by the fact that control CT is perfomed only 24 hours after 
thrombolysis. Although the half-life of t-PA is only few minutes, there is a prolonged 
effect on the coagulation cascade.  
 Fiorelli et al. and Berger et al. evaluated the ECASS I and ECASS II data and 
established that only parenchymal haematoma type 2 was associated with an increased 
risk of clinical deterioration; all other types of haematomas did not independently 
increase the risk of late deterioration. In the NINDS rtPA study 70% of the symptomatic 
HT corresponded to the parenchymal haematoma (PH1 and PH2) subtypes by ECASS 
classification. The vast majority (73,5%) of symptomatic HT in the ECASS were in the 
PH1 and PH2 subgroups. These data show that HTs accompanied by clinical worsening 
usually belong to parenchymal haemorrhages, appear as dens haematomas and they have 
pronounced space occupying effect. In our sample PH2 type transformations developed 
in thrombolysed patients and all of them were diagnosed already clinically. On the other 
hand relatively large proportion of HT1-2 and PH1 transformations were diagnosed only 
by brain autopsy even in a specialized stroke unit with multiparametric monitoring, 
despite the control CTs 24 hours later in thrombolysed patients and other control CTs 
perfomed due to clinical worsening (in 6 cases).  
 Although some prior studies demonstrated the negative impact of the 
asymptomatic HTs, even of the HI forms, on the outcome compared with those without 
HT of acute ischaemic stroke. According to a previous study, based on both imaging and 
autopsy results, the pathogenesis of haemorrhagic infarctions and parenchymal 
haematomas are different; while haemorrhagic infarctions are the consequences of 
multifocal extravasation of red blood cells, usually in the grey matter, parenchymal 
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haematomas probably represent haemorrhages from single damaged vessels, injured by 
ischaemia and following reperfusion. Since the transformation occurs in the already 
necrotic tissue, often no clinical worsening, reflecting the development of HT, could be 
detected. The general condition of acut stroke patients with fatal outcome is very poor, 
there are several additional extracerebral factors (ie. bronchopneumonia, acute 
myocardial infarction, pulmonary embolism) which may lead to the fatal outcome.  
 Instead of focusing on the reasons, clinical signs or treatment of HT, our aim 
was to emphasize the possibility and much higher than expected frequency of its 
occurrence even without clinical signs of the development and emphasize the need of 
clinical alertness even in asymptomatic cases. Since we evaluated only fatal cases, our 
results cannot be extrapolated to all ischaemic stroke cases. However keeping this in 
mind, in individual cases (e.g. in thrombolysed patients) clinicians may consider 
requesting brain CT immediately before discharging the ischaemic stroke patient. 
 Additionally we underline the importance of clinical autopsies which are still 
crucial in the correct diagnosis of HT of fatal stroke cases even in the era of advanced 
imaging techniques. Our study provided solid evidence that post-mortem 
neuropathological examination is important not only in confirming the clinical diagnosis 
but also reveals in a high proportion of patients undisclosed clinically relevant brain 
pathologies. Furthermore, post-mortem neuropathology is of educational value for 
trainees and specialists alike in clinical neurosciences, imaging and general pathology.  
 
5.2. Cell Death Mechanisms in Ischaemic Stroke 
 In human brain ischaemia the critical decrease of blood supply results in 
neuronal damage in few minutes after stroke. Acute neuronal injury causes 
overactivation of PARP-1, which results in unregulated poly(ADP-ribose) (PAR) 
synthesis and due to the ATP and NAD+ decrease, widespread neuronal cell death. 
 Only scattered neurons expressed PARP-1 in normal brain tissue, in accordance 
with previous results. Post-ischaemic nuclear expression of PARP-1 peaked in the infarct 
core and in the periinfarct area inside 3 days, which is consistent with previous human 
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results. On the other hand, by 2 days only very sparse cells contained detectable PARP-
1 within the infarcts, while in our material, the induction was evident for up to 2 weeks. 
The number of neurons with cytoplasmic PARP-1 immunoreactivity was highest in the 
periinfarct region and it correlated with increasing number of TUNEL-labeled neurons 
showing also apoptotic morphology. Regardless of the survival time, intense nuclear and 
cytoplasmic immunoreactivity were not detected in the same cells, supporting an 
ischaemia-induced subcellular translocation of PARP-1. 
 For nuclear immunoreactivity, both PARP-1 and cleaved PARP-1 correlated 
with increasing neuronal ischaemic damage score, with a delayed peak in the expression 
of cleaved PARP-1 after 3 days of ischaemia. The number of neurons with cytoplasmic 
expression of cleaved PARP-1 was in inverse correlation with increasing ischaemic 
damage. As a sign of PARP-1 enzymatic activity, PAR immunoreactivity was very 
intense both in the neuronal somas and in the cytoplasm of post-ischaemic neurons. It 
has been hypothesized that PAR is generated mainly in the nucleus and localizes to 
cytosol and interacts there with mitochondria to induce cell death. Cytoplasmic PARP-1 
has been described in normal brains in a previous study, where subcellular localization 
of PARP-1 was studied in three non-neurological patients. In another study of human 
traumatic brain injury, PARP-1 was found either exclusively in the nucleus or in both 
nuclear and cytoplasmic compartments. The dominance of cytoplasmic neuronal staining 
was linked with a short time interval from trauma to surgery. All these post-mortem 
studies carry a hazard that the changes in PARP immunoreactivity may be due to cell 
death or partial cell death, during which the nuclear content becomes more accessible to 
immunohistochemical staining. Strikingly, in the present study, PARP-1 was detected in 
nucleoli either alone or with simultaneous nuclear expression between 15 and 39 h and 
only in the periinfarct and contralateral regions, which retain more physiological energy 
metabolism than the infarct core. Although nucleolar PARP-1 expression has not been 
reported in neurons before, it has been described in vitro in MDBK, HeLa and CHO cells 
and in murine fibroblasts fitting as a sign of active RNA synthesis in general. 
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 The scattered expression of ACA-3 in controls is in line with the suggested roles 
of caspases in axon guidance, synaptic plasticity and preservation of normal brain 
integrity. Taken together, neuronal cytoplasmic ACA-3 immunoreactivity was highest in 
the periinfarct area - the area of most prevalent apoptosis. Interestingly, post-ischaemic 
ACA-3 immunoreactivity became evident in the cytoplasm of the gray matter neurons, 
although the well-established role of ACA-3 as an inactivator of the nuclear protein 
PARP-1 (as well as other nuclear substrates) would suggest a nuclear localization. In a 
previous study of human brain ischaemia ACA-3 was strongly expressed both in the 
cytoplasm and in the nucleus. Our results are in keeping with the results of Ferrer et al. 
that demonstrated the exclusive expression of ACA-3 in the cytoplasm in a Western blot 
analysis from penumbral samples of adult rats. Interestingly, post-ischaemic ACA-3 
immunoreactivity became evident in the cytoplasm of the gray matter neurons, although 
the well-established role of ACA-3 as an inactivator of the nuclear protein PARP-1 (as 
well as other nuclear substrates) would suggest a nuclear localization.  
 The present and our previous observational findings generate a hypothesis of 
overexpressed nuclear full-length and cleaved PARP-1 as a kind of surrogate marker of 
necrosis while cytoplasmic PARP-1 might reflect concomitant ongoing apoptosis. After 
a delay of some days, PARP-1 cleavage could reflect an attempt to substitute necrosis 
with apoptosis in the periinfarct region, a process requiring ATP. A previous study 
describing PARP-1 cleavage during apoptosis in vitro demonstrated that the larger p89 
PARP-1 fragment migrates from the nucleus to the cytoplasm in apoptotic cells. 
Based on a series of human atherothrombotic infarcts, it has been hypothesized 
that apoptosis makes little contribution to neuronal death in focal brain infarcts in man, 
because many neurons showed obvious morphological changes of ischaemic neuronal 
death without immunolabeling for caspase-3 in the infarcted regions. In contrast to that, 
our results support a concomitant role for apoptosis and necrosis in neuronal ischaemic 
cell death in keeping with Sairanen’s previous results demonstrating the decrease in 
TUNEL-labeling with increased necrosis.  
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There is a great interest in the potential clinical benefit of PARP-1 inhibition in 
human diseases, such as myocardial infarction, stroke and cancer based on the double-
edged role of PARP-1 in the pathogenesis of cardiovascular and inflammatory diseases 
and on the other hand on its ability to repair injured DNA. As reviewed by Graziani and 
Szabo, a vast body of literature suggests that cells with mild, repairable DNA damage as 
well as cells with severely damaged DNA are diverted by PARP-1 inhibition to a 
common pathway, i.e. apoptotic cell elimination. Caspase-3 mediated PARP-1 
inactivation by its cleavage suggests that blocking PARP-1 activation is crucial for the 
execution of apoptosis. This theory of protection against necrosis by inhibition or 
inactivation of excessive PARP-1 renders the necrotic process amenable to 
pharmacological intervention. Our results support inhibition of the pathological PARP-
1 overactivation in neurons as a therapeutic strategy in human brain ischaemia. It might 
possibly prevent cell necrosis and ensue loss of cellular energy together with 
downregulation of various pro-inflammatory signal transduction pathways. 
The major limitations of our study are that the data are descriptive (no 
possibility of interventions) and data are based only on immunohistochemical data. In 
our opinion, the autopsy brain cohort is best used for microscopical evaluation instead 
of homogenization for, e.g. Western blotting. In the latter approach, the knowledge on 
cellular localization would be lost. Due to the extensiveness of data collected by counting 
the number of positive cells (semiquantitative) under a microscope, our analysis lacks 
systematic evaluation of PARP-1, PAR, and ACA-3 immunoreactivities in other cells of 
the neurovascular unit besides neurons. Third, the autopsy cohort consists of serious, 
lethal (in many cases death due to herniation) brain infarct cases with main artery 
occlusion, which limits the interpretation of the results to a less severe stroke. 
 
5.3. The 30-Day-Outcome in Spontaneous Supratentorial Intracranial 
Haemorrhages 
Predictors of fatal outcome in primary ICH have been widely studied. However 
no reliable and widely used scoring system has been established as yet. Our aim was to 
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assess a relatively simple, reproducible, cost-effective predictive scoring system by 
analysis of a wide range of clinical and epidemiological data. Our results show that 
systolic blood pressure, serum potassium and glucose levels, and platelet count 
independently and statistically significantly predict the 30-day fatal outcome in primary 
supratentorial ICH. Therefore, we propose a predictive scoring system for clinical 
outcome in ICH using six parameters (serum glucose; total haematoma volume; systolic 
blood pressure; presence of intraventricular haemorrhage; serum potassium level; and 
age) with the acronym SUSPEKT.  
Of the laboratory parameters, we found serum glucose (SU) level on admission 
to be significantly associated with lethal outcome and this result is also supported by 
previous studies, while others reported that, in ICH, hyperglycaemia is not a significant 
and independent outcome predictor. Stead et al. described the elevated serum glucose 
level at admission as a predictor of early (<7 days) mortality both in diabetic and in 
nondiabetic patients.  
We also found that absolute and relative haematoma volumes (“S” for size), 
haematoma growth index, and presence and size of intraventricular haemorrhage are 
predictors of death within 30 days after ICH. We recommend the use of absolute 
haematoma volume since it is easier to calculate and its predictive value is similar to 
relative volume. Haematoma volume is a well-known essential predictor of mortality and 
poor outcome in patients with ICH. 
According to previous findings, high systolic and diastolic blood pressure are 
associated with larger ICH volume. High mean arterial blood pressure and diastolic 
pressure correlate significantly with mortality and poor outcome. Dandapani et al. 
demonstrated that higher than 145 Hgmm mean arterial blood pressure is unfavourable 
regarding the outcome. However, according to previous results, low blood pressure 
(below 120 Hgmm) is also associated with poor outcome. We found only systolic blood 
pressure („P”) to strongly predict 30-day fatal outcome. 
Presence and size of intraventricular haemorrhage (“E” for expansion) are also 
strongly associated with outcome in both overall and supratentorial cerebral 
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haemorrhages. Haematoma expansion is a significant determinant of both mortality and 
poor functional outcome after ICH.  
  We observed a previously unreported, very strongly significant association 
between serum potassium (“K”) level and 30-day lethal outcome, which was related to 
both high and low levels outside the normal range. According to a previous study based 
on 55 haemorrhagic stroke cases, abnormal potassium level was almost in 40% of the 
cases, mostly (34.55%) hypokalaemia and less (3.63%) hyperkalaemia, although the 
effect of these alterations on prognosis was not in focus. Another article analyses 
electrolit alterations among intracerebral haemorrhage cases. Patients with thalamus 
bleeding had significantly much frequently altered sodium, potassium and chlorid levels, 
than patients with nonthalamic bleeding. Those patients who showed electrolit 
abnormality had significantly higher mortality than those who didn’t.  
Our result could be explained also by the fact that high and low potassium levels are 
associated with morbidity and mortality also through cardiac effects: ventricular 
fibrillation and cardiac arrest. At extreme serum potassium levels death probably 
occurred because of cardiac dysfunction and not directly due to intracranial mass effect. 
 Age (“T” for lifetime) had a borderline predictive p value of 0.054 consistent 
with previous observations that the role of age in outcome after ICH is controversial. 
Some prior studies reported that age was significantly and independently correlated with 
fatal outcome, while others did not find this association or only for patients aged above 
either 65 or 80 years.  
 We identified low platelet count as a predictor of fatal outcome and it is also 
reported that low platelet count and platelet dysfunction significantly correlate with 
haematoma growth. Low haemoglobin showed no association with lethal outcome within 
30 days. Although Kumar et al. reported that anaemia and WBC count were associated 
with larger haematomas, none of these variables were predictors of 30-day mortality in 
concert with our results. 
 Time from symptom onset to initial CT was inversely and strongly associated 
with fatal outcome. This paradoxical relationship could be explained by cases of rapidly 
32 
 
worsening complaints or severe signs caused by massive haemorrhages having presented 
to hospital sooner and, in contrast, slower response by patients experiencing mild 
impairment due to small haemorrhages. 
 There was no correlation between smoking and 30-day mortality. In a Chinese 
study smoking was an independent risk factor for death in both the ischaemic and 
haemorrhagic stroke, while other reports found no association. Ikehara et al. reported 
that heavy alcohol consumption is significantly associated with increased mortality from 
haemorrhagic stroke for men; however, in the present study in accordance with others’ 
results we found no association between alcohol consumption and fatal outcome in ICH. 
 Several prognostic models have been developed to predict fatal outcome after 
ICH. Prognostic scores limited to supratentorial haemorrhages are also known. These 
studies focused on several factors: age, sex, volume or location of haemorrhage, presence 
of intraventricular haemorrhage, subarachnoidal extension of haemorrhage, presence of 
hydrocephalus on initial computed tomography scan, level of consciousness, focal 
neurological deficit on admission, high NIHSS total score, pulse pressure. Compared 
with the previously used prognostic score, undoubtable forcefulness of SUSPEKT score 
is that it includes serum potassium level which is a novelty and hyperglycaemia which 
can be corrected. Another advantage of our scoring system is that it consists of only 6 
parameters and except haematoma volume these can be managed and influenced by 
conservative (i.e. nonsurgical) therapeutic interventions. 
 Our findings are limited by some shortcomings. Prehospital deaths, exclusion 
of large, multilobar haematomas, and missing second CT in the survivor group may have 
led to possible selection bias. 
 
NEW DISCOVERIES 
 
 1) Analyzing the results of an autopsy series performed in the Neuropathology 
Laboratory Unversity of Debrecen over a two-year long period we provided solid 
evidence that post-mortem neuropathological examination is still important and essential 
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not only in confirming the clinical diagnosis but it also reveals in a high proportion of 
patients undisclosed clinically relevant brain pathologies. 
 2) According to the previous results the frequency of the HT of ischaemic stroke 
is relatively high and its occurence is often asymptomatic. The vast majority of literature 
on this topic is based on imaging techniques. Our study provides retrospective data about 
the proportion of HT diagnosed by imaging tools performed by the suggestions of actual 
guidelines and the proportion diagnosed by brain autopsies. We demonstrated that HT is 
still frequent and frequently undiscovered despite the fact that clinicians are aware of its 
possibility and take efforts to diagnose it. We also demonstrated that autopsy has a unique 
and essential role in diagnosing HT. 
3) We reported nucleolar PARP-1 expression which is a novelty. It has been 
described in vitro in MDBK, HeLa and CHO cells and in murine fibroblasts before, but 
not in neurons. In our sample PARP-1 was detected in nucleoli either alone or with 
simultaneous nuclear expression between 15 and 39 h and only in the periinfarct and 
contralateral regions, which retain more physiological energy metabolism than the 
infarct core.  
 4) The present observational findings generate a hypothesis of overexpressed 
nuclear full-length and cleaved PARP-1 as a kind of surrogate marker of necrosis while 
cytoplasmic PARP-1 might reflect concomitant ongoing apoptosis.  
 5) Our present study supports the previously in vitro demonstrated subcellular 
translocation of PARP-1 from nucleus to the cytoplasm in human ischaemic stroke.  
 6) The present study on a unique set of human post-mortem brains demonstrates 
the concomitance of necrosis and apoptosis and their relation to the extent of ischaemic 
neuronal damage in human ischaemic stroke.  
 7) We demonstrate that serum potassium concentration is significantly 
associated with fatal outcome: high and low levels outside the normal range both 
represents elevated odds of death. 
 8) The final multiple logistic regression model showed statistically significant 
associations between 30-day case fatality and a number of variables: Using serum 
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glucose (Sugar); total haematoma volume (Size); systolic blood Pressure; presence of 
intraventricular haemorrhage (Extension to the ventricular system); serum potassium 
level (Kalium) and adding age (lifeTime) which was of borderline significance we 
developed a six-factor scoring system SUSPEKT. The SUSPEKT scoring system is 
suitable for prediction of 30-day mortality after primary supratentorial ICH. Compared 
with the previously used prognostic score, undoubtable forcefulness of SUSPEKT score 
is that it includes serum potassium level which is a novelty and hyperglycaemia which 
can be corrected. Another advantage of our scoring system is that it consists of only 6 
parameters and except haematoma volume these can be managed and influenced by 
conservative (i.e. nonsurgical) therapeutic interventions.  
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